Skip to main content

Table 2 Pathologic characteristics and their association with loss of wt BRCA1 in ER-positive and ER-negative BRCA1-related breast cancers

From: Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers

Variable ER+ ER-
  Loss of wt BRCA1
N(%)
No loss of wt BRCA1
N(%)
P-value Loss of wt BRCA1N(%) No loss of wt BRCA1
N(%)
P-value
Sample Size 34 8   31 4  
First cancers 24 (70.6) 8 (100)   28 (90.3) 2 (50)  
   Mean age (range) 45.2 (29 to 68) 50.1 (33 to 72) 0.51 42 (28 to 73) 33.5 (31 to 36) 0.14
Second cancers 10 (29.4) 0   3 (9.7) 2 (50)  
   Mean age (range) 48.7 (34 to 63)    56 (53 to 61) 57 (56 to 58)  
Histology       
Ductal* 29 (85.3) 4 (50) 0.05 30 (96.8) 4 (100) 1.00
Ductal/Lobular 3 (8.8) 3 (37.5)   1 (3.2) 0  
Other 2 (5.9) 1 (12.5)   0 0  
Mitoses/10 high power field       
0 to 5* 9 (26.5) 8 (100) < 0.001* 1 (3.2) 0 1.00
6 to 10 12 (35.3) 0   2 (6.5) 0  
> 10 13 (38.2) 0   28 (90.3) 4 (100)  
Grade       
1 (3 to 5 points) 5 (14.7) 5 (62.5)   0 0  
2 (6 to 7 points) 6 (17.6) 3(37.5)   1 (3.2) 0  
3 (8 to 9 points)* 23 (67.6) 0 < 0.001* 30 (96.8) 4 (100) 1.00
Geographic Necrosis/Fibrotic Focus       
Yes 9 (26.5) 0 1.00 22 (71.0) 2 (50) 0.574
No 25 (73.5) 8 (100)   9 (29.0) 2 (50)  
Margins       
Invasive 29 (85.3) 8 (100) 1.00 15 (48.4) 2 (50) 1.00
Pushing/Circumscribed 5 (14.7) 0   16 (51.6) 2 (50)  
Lymphocyte Infiltrate       
Moderate/Severe 4 (11.8) 0 1.00 13 (41.9) 2 (50) 1.00
None/Mild 30 (88.2) 8 (100)   18 (58.1) 2 (50)  
PR       
Positive* 29 (85.3) 8 (100) 1.00 1 (3.6) 0 1.00
Positive 26 (76.5) 7 (87.5)   0   
Low Positivea 3 (8.8) 1 (12.5)   1 (3.6)   
Negative 5 (14.7) 0   27 (96.4) 4 (100)  
Unknown 0 0   3 (9.8) 0  
Her2/Neu IHC       
Positive 1 (2.9) 0 1.00 0 0 1.00
Negative 24 (70.6) 7 (87.5)   25 (80.6) 3 (75)  
Her2/Neu FISH       
Positive 1 (2.9) 1 (12.5)   0 1 (25)  
Negative 6 (17.6) 0   5 (16.1) 0  
Equivocald 2 (5.9) 0   1 (3.2) 0  
  1. Abbreviations: ER, estrogen receptor; PR, progesterone receptor; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.
  2. Loss of wt: cancers with LOH with loss of wt BRCA1 allele.
  3. No loss of wt: includes cancers with no LOH and LOHmut .
  4. Percentages calculated by column.
  5. a Low PR positive: 1 to 10% cells show nuclear staining for PR.
  6. b HER2 positive: HER2:CEP17 ratio by FISH > 2.2 or IHC 3+ (no FISH performed).
  7. c HER2 negative: HER2:CEP17 ratio by FISH < 1.8 or IHC < 3+ (no FISH performed).
  8. d HER2 equivocal: HER2:CEP17 ratio by FISH 1.8 to 2.2.
  9. * P-value retained significance with Bonferroni adjustment for multiple comparisons.